Iterative Scopes, a pioneer in precision medicine technologies for gastroenterology, announced today that it has acquired Clinical Research Strategy Group, LLC and Precision Research (CRSG/Precision), two clinical trial optimization companies focused on streamlining and accelerating the drug development process for inflammatory bowel disease (IBD).
The acquisitions deepen Iterative Scopes’ ties to the IBD clinical research community and strengthen its knowledge of the end-to-end research process with a focus on provider viewpoints and pain points. Ultimately, these acquisitions will improve patient outcomes by accelerating the development of improved treatment options. The President and CEO of both companies, Chris Fourment, MD, a leading expert on clinical trials in IBD, has joined Iterative Scopes as SVP of Clinical Strategy.
